Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA

Noth, Imre; Oelberg, David; Kaul, Manika; Conoscenti, Craig; Raghu, Ganesh

doi:10.1183/13993003.02106-2017

Public

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA

Published in European Respiratory Journal • May 24, 2018

Authors:

Imre Noth

David Oelberg

Manika Kaul

Abstract

Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) in more than 60 countries, including the USA [1]. In the two phase III INPULSIS trials, nintedanib reduced disease progression by reducing decline in forced vital capacity [2]. Most patients were able to manage the...

Subject

Nintedanib

Tolerability

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!